SCHEMBL257412

SCHEMBL257412

Fc1ccc(-c2cc(Cl)nc3c(-c4ccc(Cl)cc4)c(C4CC4)nn23)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.42
ARF6 P62330 2/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
ATM Q13315 1/20 0.39
MAPT P10636 3/20 0.36
RAB9A P51151 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HTT P42858 2/20 0.36
PRKAA2 P54646 1/20 0.36
PSD A5PKW4 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
NPC1 O15118 1/20 0.34
MARS1 P56192 1/20 0.34
SRC P12931 1/20 0.33
BRAF P15056 1/20 0.33
KDR P35968 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15121544 0.81 ARF6 (0.41) TP53ARF6MEN1KMT2AATM
SCHEMBL257411 0.78 FPR2 (0.43) TP53ARF6MEN1KMT2AATM
SCHEMBL15021379 0.78 FPR2 (0.43) TP53ARF6MEN1KMT2AATM
Pyrimidine SCHEMBL15020692 0.75 ARF6 (0.37) TP53ARF6MEN1KMT2AATM
SCHEMBL257382 0.74 TP53 (0.53) TP53MEN1KMT2AMAPTALDH1A1
SCHEMBL257503 0.71 ALDH1A1 (0.50) TP53KMT2AMAPTALDH1A1HTT
SCHEMBL15020632 0.70 TP53 (0.79) TP53MEN1KMT2AMAPTRAB9A
SCHEMBL15020590 0.70 FPR2 (0.38) TP53ARF6LMNA
SCHEMBL15020753 0.69 FPR2 (0.41) ARF6MARS1
SCHEMBL15042260 0.69 BCL6 (0.43) TP53MAPTNPSR1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 TP53 4550/4885ARF6 1261/4885MEN1 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.